Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts ...

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.

As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug ...

From exploring the wonders of plants as a curious teen to leading global initiatives at SCIEX, Gitte Barknowitz has carved ...

Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization ...

The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.

At the forefront of precision dosing, Sharmeen leads DoseMe's efforts to transform personalized medicine from lab research to bedside application. With a background in pharmacy and specialized ...